ADHD: Medical Treatments
The question
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the General Medical Council on the (a) effectiveness and (b) adequacy of that organisation's guidance entitled Good practice in proposing, prescribing, providing and managing medicines and devices, published on 5 April 2021, on shared care agreements for people with ADHD.
Answered by Dr Zubir Ahmed
Building on the work of the independent ADHD Taskforce, on 4 December 2025 my Rt Hon. Friend, the Secretary of State for Health and Social Care, announced an independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism, which will inform our approach to ensuring appropriate support is in place.
The independent review published an interim report on the 31 March 2026 which sets out key findings from the data and evidence reviewed so far, learning to date from discussions with people, including people with lived experience, and organisations as well as setting out plans for the next phase of the review and the key questions to address in more detail.
The Department has made no specific assessment of the effectiveness of shared care agreements with independent sector providers for patients prescribed ADHD medication or held discussions with General Medical Council on their guidance.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →